Search This Blog

Wednesday, May 27, 2026

Nuvalent gets FDA Priority Review for neladalkib NDA, PDUFA November 27

 

Nuvalent gets FDA Priority Review for neladalkib NDA, PDUFA action date set for November 27, 2026

  • Neladalkib is an ALK inhibitor targeted in Nuvalent's New Drug Application now under FDA Priority Review.
  • Nuvalent appoints Georg Pirmin Meyer, M.D., as Chief International Officer to lead global expansion.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)